🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Baxter International Inc. BAX SPXR3KPHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.baxter.com
Company Profile ↓
$25.83
+8.05% 1Y
Mkt Cap$13.35B
P/E-13.74
P/B2.30
Div. Yield0.15%
52W High$28.34
52W Low$15.79
Book Value$12.00
EPS (TTM)$-1.88

Company Overview

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $11.24B (+5.7% YoY); net profit $-957.00M.
  • Trailing 12 Months Year-on-year growth — revenue +5.3%, earnings +36.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR -0.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-0.01%
1 Year:5.30%

Compounded Profit Growth

5 Years:-
1 Year:36.80%

Stock Price Performance

1 Year:+8.05%
6 Months:+46.15%
3 Months:+33.33%
1 Month:-4.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 80% of range
$15.79 $28.34
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)51.10 · Neutral
Price Performance
1M-4.33%
3M+33.33%
6M+46.15%
1Y+8.05%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -0.0% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-13.74
Industry PE
25.17
Forward P/E
12.53
PEG Ratio
36.68
Book Value
$12.00
Price to Book
2.30
P/S
1.24
EV/EBITDA
11.39
Dividend Yield
0.15%

Growth (CAGR)

Revenue 5Y
-0.01%
Profit 5Y
-
Revenue (YoY)
5.30%
Earnings (YoY)
36.80%

Profitability & Returns

ROCE
1.04%
ROE
-14.37%
ROA
2.85%
Profit Margin
-9.27%
Op Margin
14.43%
Gross Margin
34.10%
EPS (Latest Qtr)
$0.24
EPS (TTM)
$-1.88

Balance Sheet & Liquidity

Debt/Equity
1.56
Quick Ratio
1.13
Current Ratio
1.95
Debt
$9.67B
Total Assets
$19.79B
Current Assets
$6.85B
Working Capital
$3.90B

Ownership

Promoter Holding
0.34%
Chg in Prom Hold
0.00%
FII / Inst Holding
110.19%
Chg in FII Hold
0.04%

Financial Snapshot

Enterprise Value
$13.35B
Total Revenue (TTM)
$11.47B
EBITDA
$1.88B
Free Cash Flow
$1.00B
Operating Cash Flow
$1.32B
Shares Outstanding
517.00M
Gross Margin
34.10%
Payout Ratio
307.69%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BAX Baxter International Inc. SPXR3KPHARMA 25.83 -13.74 $13.35B 0.15% 1.04% -14.37% -0.01% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ---2.48B2.60B2.71B2.77B2.69B2.81B2.76B2.83B2.64B2.83B2.85B3.04B2.80B2.72B2.97B3.18B2.95B3.10B3.23B3.56B3.59B3.61B3.75B2.44B2.59B2.60B2.73B2.49B2.69B--2.62B2.81B2.83B2.97B2.70B2.96B
Cost of Revenue ----------------------------------1.76B1.82B1.89B2.40B1.81B-
Gross Profit 972.00M1.07B1.10B1.04B1.13B1.13B1.16B1.12B1.22B1.23B1.18B1.08B1.15B1.23B1.30B1.16B1.04B1.20B1.19B1.15B1.23B1.32B1.26B1.37B1.04B1.39B964.00M1.03B1.06B1.10B961.00M1.03B--861.00M991.00M950.00M577.00M891.00M1.03B
Operating Expenses ----------------------------------803.00M800.00M778.00M821.00M825.00M-
Operating Income 68.00M186.00M-353.00M347.00M300.00M-434.00M377.00M382.00M391.00M383.00M350.00M503.00M-409.00M331.00M470.00M-390.00M424.00M513.00M163.00M264.00M-2.88B-129.00M-17.00M179.00M-115.00M179.00M--58.00M191.00M172.00M-244.00M66.00M217.00M
EBITDA ----------------------------------325.00M462.00M426.00M-447.00M309.00M-
Interest Expense ----------------------------------81.00M72.00M68.00M69.00M78.00M-
Pretax Income -----------------------------------3.00M133.00M121.00M-756.00M-6.00M-
Tax Provision -----------------------------------67.00M11.00M172.00M279.00M11.00M-
Net Income 1.21B130.00M243.00M272.00M265.00M251.00M-71.00M382.00M341.00M518.00M305.00M342.00M313.00M369.00M-23.00M332.00M246.00M356.00M168.00M298.00M298.00M450.00M71.00M252.00M-2.94B181.00M44.00M-141.00M2.51B245.00M37.00M-314.00M--126.00M91.00M-46.00M-1.13B-15.00M126.00M
Diluted EPS 2.190.240.440.490.480.45-0.130.690.620.950.570.660.600.71-0.050.640.480.690.330.580.590.890.140.50-5.830.360.09-0.284.930.480.07-0.61---0.030.18-0.09-2.19-0.030.24
R&D Expense 195.00M159.00M-127.00M155.00M150.00M-141.00M172.00M166.00M175.00M129.00M166.00M144.00M-146.00M117.00M123.00M-128.00M139.00M129.00M150.00M148.00M151.00M-164.00M165.00M133.00M-120.00M130.00M129.00M-140.00M134.00M118.00M-139.00M129.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 11.26B12.35B12.56B12.84B13.89B13.94B9.41B10.72B9.97B10.16B10.58B11.10B11.36B11.67B-10.06B10.36B10.64B11.24B
Cost of Revenue ---------------6.51B6.21B6.65B7.87B
Gross Profit 5.52B6.13B6.53B5.96B7.05B7.13B4.16B4.58B4.15B4.12B4.47B4.76B4.76B4.59B-3.55B4.15B3.98B3.38B
Operating Expenses ---------------3.58B3.44B3.54B3.20B
Operating Income ------496.00M656.00M449.00M745.00M1.29B1.58B1.77B1.62B--33.00M707.00M439.00M177.00M
EBITDA ----------------1.76B1.73B1.12B766.00M
Interest Expense ---------------413.00M508.00M408.00M290.00M
Pretax Income ----------------3.25B242.00M-289.00M-505.00M
Tax Provision ----------------135.00M61.00M37.00M395.00M
Net Income 1.71B2.01B2.21B1.42B2.22B2.33B2.01B2.50B968.00M4.96B602.00M1.55B1.00B1.10B--2.43B2.66B-649.00M-957.00M
Diluted EPS 2.613.163.592.393.884.183.664.561.769.011.082.831.932.13--4.835.25-1.27-1.87
R&D Expense 760.00M868.00M917.00M915.00M946.00M1.08B582.00M610.00M603.00M646.00M615.00M654.00M595.00M521.00M531.00M450.00M518.00M590.00M518.00M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --15.40B17.35B17.49B19.07B20.39B25.22B26.14B20.96B15.55B17.11B-16.84B16.52B16.80B15.72B16.24B17.50B18.19B20.02B-28.29B28.28B25.78B20.05B
Current Assets ----------------------8.01B9.60B8.85B6.87B
Cash & Equivalents 2.48B2.54B2.13B2.79B2.69B2.90B3.27B2.73B2.92B2.21B2.80B3.39B-2.95B2.86B2.86B1.84B1.90B2.93B3.33B3.73B-1.72B3.08B1.76B1.97B
Inventory ----------------------2.68B1.92B2.05B2.23B
Receivables ----------------------2.57B1.72B1.68B1.86B
Total Liabilities -----------8.00B-7.78B7.69B7.71B7.85B8.65B9.70B10.28B11.29B-22.39B19.81B18.76B13.95B
Current Liabilities --3.63B4.46B4.04B4.86B4.76B5.25B6.04B5.75B2.74B2.82B-2.60B2.59B2.66B2.81B3.28B2.56B3.23B3.33B-4.75B6.50B6.51B2.97B
Long Term Debt --------------------6.23B-15.23B11.09B10.37B9.47B
Total Debt ----------------------17.20B14.11B13.45B9.78B
Total Equity -7.01B6.23B7.19B6.57B6.58B6.94B8.46B8.12B8.85B8.29B9.12B-161.00M9.07B8.84B9.11B7.84B7.57B7.78B7.88B8.69B-5.83B8.40B6.96B6.13B
Shares Outstanding ----------------------683.49M683.49M683.49M683.49M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 2.31B2.52B2.91B3.00B2.82B3.11B3.20B3.21B1.77B1.65B1.71B2.02B2.10B1.87B-1.21B1.73B1.02B845.00M
Investing Cash Flow -305.00M-993.00M-1.15B-1.26B-1.43B-1.57B-5.36B-1.54B-1.81B-715.00M-1.29B-916.00M-1.10B-1.18B--931.00M3.21B-626.00M2.84B
Financing Cash Flow -1.97B-1.93B-1.01B-1.72B-1.14B-1.11B1.65B-1.40B-481.00M-324.00M93.00M-2.60B498.00M-345.00M--1.44B-3.49B-1.08B-4.22B
Capital Expenditure ----------------635.00M-436.00M-460.00M-522.00M
Free Cash Flow ---------------576.00M1.29B559.00M323.00M
Net Change in Cash ----------------1.16B1.45B-688.00M-530.00M
Share Buybacks 1.85B1.99B1.22B1.45B1.58B1.48B913.00M550.00M-292.00M564.00M2.45B1.27B500.00M600.00M32.00M00-

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 49.0%49.6%51.9%46.4%50.7%51.2%44.2%42.7%41.6%40.5%42.3%42.9%41.9%39.3%-35.3%40.1%37.5%30.1%
Operating Margin % ------5.3%6.1%4.5%7.3%12.2%14.3%15.6%13.8%--0.3%6.8%4.1%1.6%
Net Margin % 15.2%16.3%17.6%11.1%16.0%16.7%21.4%23.3%9.7%48.9%5.7%13.9%8.8%9.4%--24.2%25.6%-6.1%-8.5%
ROE % 24.4%32.3%30.7%21.6%33.8%33.5%23.8%30.8%10.9%59.9%6.6%19.7%12.7%12.7%--41.7%31.6%-9.3%-15.6%
ROCE % ------2.5%3.3%3.0%5.8%9.0%12.3%11.8%9.7%--0.1%3.2%2.3%1.0%

Shareholding Pattern

Insiders
0.34%
Institutions
110.19%
Public Float
110.57%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 15.83% 81.84M $2.14B
2 Pzena Investment Management LLC 12.63% 65.30M $1.71B
3 Dodge & Cox Inc. 11.29% 58.39M $1.53B
4 FMR, LLC 10.43% 53.91M $1.41B
5 Vanguard Capital Management LLC 6.53% 33.75M $882.00M
6 Vanguard Portfolio Management LLC 4.65% 24.06M $628.61M
7 State Street Corporation 3.98% 20.60M $538.29M
8 Greenhaven Associates, Inc. 2.76% 14.29M $373.27M
9 Geode Capital Management, LLC 2.73% 14.12M $369.05M
10 Invesco Ltd. 2.39% 12.36M $323.02M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BAX

Google News Mon, 07 Sep 2026

BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPTF9fTEpRcVh1T3BZVHFrdWZ4RFl5MWdmNmNmLXBlbWV4dmJHTTRjR0ZCYkpLUmpjejhXc2JuejJ1bG5NRHJFN2FyNGVvZ1Q2c0JpQnFNQTFyaGhVZXNaMlVfLTZ0dFVtR1MyM1NvQW5BZmJFVm5uQ2NRenIwVW56RmU1M2M1LVhQMFM3Q2…

Google News Fri, 04 Sep 2026

BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQVHZfNDh4VGozbkdqTGpzdklycUJsWEN6bXR1UjY2RGtyaUt6NTRlV0xjdGtUSEtjMHJ3azNNS1VPY0p2OExQQVRNaTk4aHRHdkpNOWJTRXlKYUdvTW9JYlgwREU4T01zZGZDbnpiZXl4T3lIdVBYMFh2MGVYOEdvcjFOTTdoTDJObUNLND…

Google News Fri, 31 Jul 2026

Baxter International (BAX) Stock Cools As Margin Pressure Tempers Guidance Lift - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNNk9WOG5TdFdqNVJ2aWlsV1ZNTFg2ZU1FalY3bDU0cFF0N1hScHQ1cVUzNjBEbEF4TlZmV3ZTVWxDNmN0amdOUmtqM05RRmVTZDF0Y2Rac3UwY2NWVDMtOTdvTE5US0piU0pRMFBHVFV4ZUdoTGphdXI5Zzl6aTZGcVo5YzZoSWtZbUt0Nl…

Google News Sat, 18 Jul 2026

Baxter: The Chart Points Higher, Valuation And Growth Are Less Appealing - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSXlMMGctNy1QendpU0NIczk1Q2djWkhYNEpOMHg4clBYdWpvVlYteGJmNlFURzIteVNXVFhKSXZmb1VodGNOT2N0dXp0eW9DZlhWUWQwRkpUdlN2d09MeVAzX3NwdjR4SV9nYXp4ZFU4dUkzamRrVUs4RzBZVVFvd1VkNENRenB0ak1KdF…

Google News Fri, 31 Jul 2026

Why Baxter International Stock Skyrocketed by 19% This Week - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUTA4R3JqWUhsWTZ4TzJoV2NqTnFQV1BOUzRqUVZ6RllFMzFsZTlDcDROUGZQbWhXeGZLbDhEcnBVUWJHT0tZVlBSU0hSbnQyY2xzdWlhNGd6c0Z3WTlYSXNMbzV2T3Rfb2VFcDhFWnBiVnd1SFlmbGhocjB3Tjl2MS1VR0FUTVVIM0lHaG…

Google News ue, 26 May 2026

BAX - Baxter International Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE0tZEp0N29JZkloV2dieEZwMU1JanR1a21YSHJYLW4xNnJsUzI4M0E2LWsySW9Uc2E4NGVSYVAzYW8tOWY5?oc=5" target="_blank">BAX - Baxter International Inc Stock Price and Quote</a>&nbsp;&nbsp;<font c…

BAX — Frequently Asked Questions

What is the current share price of Baxter International Inc. (BAX)?

As of 2026-09-07 16:24 PDT, Baxter International Inc. (BAX) trades at $25.83 on NYSE. Its 52-week range is $15.79 to $28.34.

What is the market capitalisation of BAX?

Baxter International Inc. (BAX) has a market capitalisation of $13.35B on NYSE.

What is the P/E ratio of BAX?

BAX trades at a trailing price-to-earnings (P/E) ratio of -13.74. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.30.

Does BAX pay a dividend?

Baxter International Inc. (BAX) currently offers a dividend yield of 0.15%.

What is the return on equity (ROE) of BAX?

BAX has a return on equity (ROE) of -14.37%. Its return on capital employed (ROCE) is 1.04%.

Is BAX a good stock to buy?

This page provides a data-driven analysis of Baxter International Inc. (BAX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space